1. 1-16 of 16
    1. First Tool to Assess Impact of Co-illnesses in Young Cancer Patients

      First Tool to Assess Impact of Co-illnesses in Young Cancer Patients

      "Little or no improvement in cancer survival rates has been achieved in this age group for decades. These patients too frequently fall between pediatric and adult oncology. The study, funded by the National Cancer Institute (NCI), is part of the Adolescent & Young Adult Health Outcomes & Patient Experience (AYA HOPE) Study designed to address the disparities.  Previous studies show that having comorbidities adversely affect treatment, quality of life, service needs, and survivorship care in adult cancer survivors. Co-illnesses may increase the toxicity of specific treatments, increase hospitalizations, create difficulties with treatment, and lead to higher health care costs and death."

      Read Full Article
    2. Risk of Several Autoimmune Diseases Increased in Childhood Cancer Survivors

      Risk of Several Autoimmune Diseases Increased in Childhood Cancer Survivors

      "Similarly, childhood cancer survivors had significantly higher rates than expected of rheumatic heart disease, scleroderma (connective tissue disease), idiopathic thrombocytopenic purpura (tendency to bleed and bruise easily due to low clotting factor levels), Hashimoto's thyroiditis, pernicious anaemia, sarcoidosis (abnormal cell clumping), Sjögren syndrome (a tear duct and salivary gland disorder), and diabetes."

      Read Full Article
    3. Number of childhood cancer survivors is increasing and most have morbidities

      "Phillips and colleagues estimated the number of childhood cancer survivors in the United States to be 388,501, which is an increase of 59,849 from the previous estimate made in 2005 by a team from the National Cancer Institute (NCI). Of these survivors, about 84% had survived 5 years or more post-diagnosis.  Approximately 70% of the survivors of childhood cancers were estimated to have a mild or moderate chronic condition, and about 32% were estimated to have a severe, disabling, or life-threatening chronic condition.  An estimated 35% of the survivors, ages 20 to 49 years, had neurocognitive dysfunction; approximately ...

      Read Full Article
    1-16 of 16
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video